J. Blaser

发表

Negligible impact of highly patient-specific decision support for potassium-increasing drug-drug interactions - a cluster-randomised controlled trial.

Emmanuel Eschmann, P. Beeler, Patrick E Beeler, 2019, Swiss medical weekly.

Use of an On-demand Drug–Drug Interaction Checker by Prescribers and Consultants: A Retrospective Analysis in a Swiss Teaching Hospital

Emmanuel Eschmann, P. Beeler, Jürg Blaser, 2013, Drug Safety.

Earlier switching from intravenous to oral antibiotics owing to electronic reminders.

R. Weber, P. Beeler, E. Eschmann, 2015, International journal of antimicrobial agents.

Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model

J. Blaser, S. Zinner, B. B. Stone, 1985, Antimicrobial Agents and Chemotherapy.

Aminoglycoside monitoring: timing of peak levels is critical.

H. Simmen, J. Blaser, R. Lüthy, 1985, Therapeutic drug monitoring.

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

J. Blaser, Jürg Blaser, 1985, The Journal of antimicrobial chemotherapy.

Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients

T. Lüscher, N. Kucher, E. Eschmann, 2009, Journal of thrombosis and haemostasis : JTH.

Comparative Analysis of Intravenous to Oral Transitions at Two Tertiary Care Hospitals in the U.S. and Switzerland

Patrick E. Beeler, David W. Bates, Jürg Blaser, 2017, American Medical Informatics Association Annual Symposium.

Biological variability of multiple dose pharmacokinetics of netilmicin in man

P. Niederer, J. Blaser, H. Rieder, 2004, European Journal of Clinical Pharmacology.

Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection.

J. Blaser, P. Vergères, 1992, The Journal of infectious diseases.

Once-daily dosing of aminoglycosides

J. Blaser, C. König, 1995, European Journal of Clinical Microbiology and Infectious Diseases.

Peripheral database module for clinical management and research in sleep medicine.

E. Russi, K. Bloch, J. Blaser, 1999, Technology and health care : official journal of the European Society for Engineering and Medicine.

In vitro models for the study of combination antibiotic therapy in neutropenic patients.

M. Dudley, J. Blaser, S. Zinner, 1986, The American journal of medicine.

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

J. Blaser, S. Zinner, B. B. Stone, 1987, Antimicrobial Agents and Chemotherapy.

Monitoring serum concentrations for once-daily netilmicin dosing regimens.

H. Simmen, J. Blaser, C. König, 1994, The Journal of antimicrobial chemotherapy.

Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV‐infected patients

M. Opravil, W. Fierz, J. Blaser, 1991, Clinical and experimental immunology.

Comorbidities Associated with Worse Outcomes Among Inpatients Admitted for Acute Gastrointestinal Bleeding

P. Beeler, M. Cheetham, E. Battegay, 2021, Digestive Diseases and Sciences.

Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection

M. Dudley, J. Blaser, S. Zinner, 1990, Antimicrobial Agents and Chemotherapy.

Analysis of pH and pO2 in abscesses, peritoneal fluid, and drainage fluid in the presence or absence of bacterial infection during and after abdominal surgery.

H. Simmen, J. Blaser, Hans-Peter Simmen, 1993, American journal of surgery.

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

H. Simmen, W. Siegenthaler, J. Blaser, 1981, Antimicrobial Agents and Chemotherapy.

Biomedical informatics in Switzerland: need for action.

C. Lovis, J. Blaser, 2015, Swiss medical weekly.

Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections.

H. Simmen, J. Blaser, R. Lüthy, 1995, The Journal of antimicrobial chemotherapy.

Bacterial concentrations in pus and infected peritoneal fluid--implications for bactericidal activity of antibiotics.

H. Simmen, J. Blaser, C. König, 1998, The Journal of antimicrobial chemotherapy.

Effect of pathological changes of pH, pO2 and pCO2 on the activity of antimicrobial agents in vitro

H. Simmen, J. Blaser, C. König, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Impact of Bacterial Biofilm Formation on In Vitro and In Vivo Activities of Antibiotics

W. Zimmerli, J. Blaser, Z. Rajacic, 1998, Antimicrobial Agents and Chemotherapy.

In vivo verification of in vitro model of antibiotic treatment of device-related infection

A. Widmer, W. Zimmerli, J. Blaser, 1995, Antimicrobial agents and chemotherapy.

Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.

K. Mayer, M. Dudley, J. Blaser, 1991, The Journal of infectious diseases.

Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin

M. Dudley, J. Blaser, S. Zinner, 1986, Antimicrobial Agents and Chemotherapy.

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model

J. Blaser, S. Zinner, B. B. Stone, 1985, Antimicrobial Agents and Chemotherapy.

Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.

J. Blaser, 1991, The Journal of antimicrobial chemotherapy.

In vitro models for the study of antibiotic activities.

J. Blaser, S. Zinner, 1987, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

entry of clavulanic acid into CSF of human adults without meningeal inflammation and (3) to obtain some information on the in-vitro stability of clavulanic acid

W. Siegenthaler, J. Blaser, R. Munch, 2005 .

Human pharmacokinetics and CSF penetration of clavulanic acid.

W. Siegenthaler, J. Blaser, R. Münch, 1981, The Journal of antimicrobial chemotherapy.

Human Pharmacology of Cefotaxime (HR 756), a New Cephalosporin

W. Siegenthaler, J. Blaser, R. Lüthy, 1979, Antimicrobial Agents and Chemotherapy.

Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques

John J. Wright, R. Olsen, S. Garattini, 1987, Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques.

The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy.

B. Joos, S. Kunz, J. Blaser, 1995, The Journal of antimicrobial chemotherapy.

Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia

B. Joos, M. Opravil, J. Blaser, 1995, Antimicrobial agents and chemotherapy.

Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

H. Simmen, W. Siegenthaler, A. Bonetti, 1982, Antimicrobial agents and chemotherapy.

Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy

B. Joos, M. Opravil, J. Blaser, 1993, Infection.

Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters

J. Blaser, H. Rieder, R. Lüthy, 1991, Antimicrobial Agents and Chemotherapy.

Developing strategies for predicting hyperkalemia in potassium-increasing drug-drug interactions

Patrick E. Beeler, Jürg Blaser, Emmanuel Eschmann, 2017, J. Am. Medical Informatics Assoc..

Two compartment kinetic model with multiple artificial capillary units.

J. Blaser, J Blaser, B B Stone, 1985, The Journal of antimicrobial chemotherapy.

In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.

J. Blaser, S. Zinner, 1986, The Journal of antimicrobial chemotherapy.

Human pharmacology of 5-epi-sisomicin (Sch 22591) following intramuscular administration.

J. Blaser, R. Münch, R. Lüthy, 1987, Journal of Antimicrobial Chemotherapy.

Increase of amikacin half-life during therapy in patients with renal insufficiency

J. Blaser, R. Lüthy, S. Rüttimann, 1983, Antimicrobial Agents and Chemotherapy.

Long-term accuracy of fluorescence polarization immunoassays for gentamicin, tobramycin, netilmicin and vancomycin.

B. Joos, J. Blaser, R. Lüthy, 1989, The Journal of antimicrobial chemotherapy.

Effect of pO2 and pH on synergy of tazobactam and β-lactam antibiotics against β-lactamase producing Enterobacteriaceae

J. Blaser, C. König, 1995 .

Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate.

J. Blaser, A. Bauernfeind, J. Pechère, 1990, The Journal of antimicrobial chemotherapy.

Comparative study on antagonistic effects of low pH and cation supplementation on in-vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa.

J. Blaser, R. Lüthy, 1988, The Journal of antimicrobial chemotherapy.

Sustained impact of electronic alerts on rate of prophylaxis against venous thromboembolism

P. Beeler, N. Kucher, J. Blaser, 2011, Thrombosis and Haemostasis.

Tools in a clinical information system supporting clinical trials at a Swiss University Hospital

Michael Weisskopf, Jürg Blaser, J. Blaser, 2014, Clinical trials.

Analysis of pH, pO2 and pCO2 in drainage fluid allows for rapid detection of infectious complications during the follow-up period after abdominal surgery

H. Simmen, P. Giovanoli, J. Blaser, 1994, Infection.

Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model

J. Blaser, S. Schwank, Jürg Blaser, 1996, Antimicrobial agents and chemotherapy.

Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci.

P. Francioli, U. Flúckiger, J. Blaser, 1994, The Journal of infectious diseases.

Effect of peritoneal fluid pH on outcome of aminoglycoside treatment of intraabdominal infections

H. Simmen, T. Kossmann, J. Blaser, 1993, World Journal of Surgery.

Impact of electronic reminders on venous thromboprophylaxis after admissions and transfers.

P. Beeler, E. Eschmann, J. Blaser, 2014, Journal of the American Medical Informatics Association : JAMIA.

[Challenges of Digital Medicine].

J. Blaser, 2018, Praxis.

Autosterilization of biodegradable implants by injection molding process.

E Wintermantel, K Ruffieux, E. Wintermantel, 1997, Journal of biomedical materials research.

Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats

P. Francioli, M. Bickle, U. Flúckiger, 1994, Antimicrobial Agents and Chemotherapy.

Chronic Pain: How Challenging Are DDIs in the Analgesic Treatment of Inpatients with Multiple Chronic Conditions?

R. Saller, L. Zimmerli, C. Minder, 2017, PloS one.

Use of an in-vitro kinetic model to study antibiotic combinations.

J. Blaser, S. Zinner, B. B. Stone, 1985, The Journal of antimicrobial chemotherapy.

Computer-controlled in-vitro simulation of multiple dosing regimens.

B. Ledergerber, J. Blaser, R. Lüthy, 1985, The Journal of antimicrobial chemotherapy.

Human pharmacokinetics of ceftazidime in comparison to moxalactam and cefotaxime—abstract

H. Simmen, W. Siegenthaler, A. Bonetti, 1981 .

Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug–drug interactions

P. Beeler, V. Kaplan, E. Eschmann, 2014, European Journal of Clinical Pharmacology.

Clinical decision support for monitoring drug-drug-interactions and potassium-increasing drug combinations: need for specific alerts.

P. Beeler, V. Kaplan, E. Eschmann, 2012, Studies in health technology and informatics.

Evaluation of Alerts for Potassium-Increasing Drug-Drug-Interactions

Patrick E. Beeler, Jürg Blaser, Emmanuel Eschmann, 2013, MedInfo.

A FHIR-Based eConsent App for the Digital Hospital

Manuela Weber, Alexandra Griessbach, Regina Grossmann, 2020, MIE.

[Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].

J. Blaser, A. Bauernfeind, R. Lüthy, 2008, Deutsche medizinische Wochenschrift.

[Challenges of Digital Medicine].

J. Blaser, 2018, Praxis.